REGN7508 Versus Acetylsalicylic Acid (ASA) for Venous Thromboprophylaxis After Total Knee Arthroplasty in Adult Participants

PHASE3Not yet recruitingINTERVENTIONAL

Enrollment

2,000

Participants

Timeline

Start Date

December 5, 2025

Primary Completion Date

July 16, 2027

Study Completion Date

July 16, 2027

Conditions

Symptomatic Venous Thromboembolism (VTE)

Interventions

DRUG

REGN7508

Administered per the protocol

DRUG

Acetylsalicylic Acid (ASA)

Administered per the protocol

DRUG

Placebo

Administered per the protocol

All Listed Sponsors

lead

Regeneron Pharmaceuticals

INDUSTRY